摘要
Abstract
·AIM:To observe the efficacy and the safety of low-dose mitomycin-C (MMC) in the treatment of pterygium.·METHODS:In a prospective,randomized and controlled clinical trial,a total of 550 eyes of 400 patients diagnosed with pterygium were randomly divided into the four groups-group 1:130 eyes of 100 patients,without MMC;group 2:140 eyes of 100 patients,with 0.2g/L MMC;group 3:150 eyes of 100 patients,with 0.3g/L MMC;group 4:130 eyes of 100 patients,with 0.4g/L MMC.They underwent the excision of primary pterygium barely the sclera.Visual acuity,intraocular pressure (IOP),extraocular movement,iridocyclitis,scarring, symptoms (tearing,photophobia,foreign body sensation) and signs (conjun-ctival hyperemia,ulcer of sclera and cornea,perforation of sclera) of subjects,were recorded on the day of enrollment,and after the surgery,on 2 weeks,2 months,6 months,and 1 year.·RESULTS:In group 3 and group 4,the recurrence of pterygium after the excision were less than that in group 1 and group 2 ( P < 0.01 ).In group 4,after the surgery,there were more probability of raising lOP,iridocyclitis,symptoms and signs than that in group 1,2,and 3.·CONCLUSION:Low-dose MMC is effective in the treatment of preventing the recurrence of primary pterygium.Its efficacy rises along with its density.And meantime,the safety of the treatment of low-dose MMC declines.关键词
低浓度/丝裂霉素/翼状胬肉/复发Key words
low-dose/mitomycin-C/pterygium/recurrence分类
医药卫生
